Compare Dropbox Inc (DBX) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Enveric Biosciences Inc — how do they compare? Dropbox Inc trades at $34.15 (market cap $7.42B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: Dropbox Inc is far larger — about 1091.2× Enveric Biosciences Inc's market cap, and Dropbox Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Enveric Biosciences Inc for 14 Days on average.
| DBX | ENVB | |
|---|---|---|
Market Cap | $7.42B | $6.80M |
Volume | 3,061,580 | 64,867 |
Sector | Technology | Health |
52-Week High | $37.74 | $10.80 |
52-Week Low | $22.06 | $1.27 |
Typical Hold Time | 97 Days | 14 Days |
Enterprise Value | $10.29B | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $33.08, down 1.93% amid bearish technical signals and mixed analyst sentiment. The company maintains strong profitability with 79.72% gross margins and has beaten earnings estimates for three consecutive quarters. However, negative shareholder equity and recent insider selling create headwinds. Technical indicators show bearish momentum with support at $32 and resistance at $34.
Outlook remains cautious despite solid fundamentals. The stock faces valuation concerns with a P/E of 18.86 and mixed analyst ratings (37.5% buy, 31.25% hold/sell each). Key risks include stagnant revenue growth, high debt levels, and competitive pressures in cloud storage. The consensus price target of $26.83 suggests potential downside from current levels.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
